Stemline Therapeutics Inc (STML) Stock Rating Reaffirmed by Wedbush

Stemline Therapeutics Inc (NASDAQ:STML)‘s stock had its “outperform” rating restated by Wedbush in a research note issued to investors on Saturday. They currently have a $11.00 target price on the biopharmaceutical company’s stock. Wedbush’s target price suggests a potential upside of 30.18% from the stock’s current price.

Other research analysts also recently issued research reports about the stock. HC Wainwright set a $34.00 price objective on shares of Stemline Therapeutics and gave the stock a “buy” rating in a report on Sunday, January 8th. Roth Capital restated a “buy” rating and set a $32.00 price objective on shares of Stemline Therapeutics in a report on Wednesday, December 7th. Jefferies Group LLC set a $23.00 price objective on shares of Stemline Therapeutics and gave the stock a “buy” rating in a report on Sunday, December 4th. Ladenburg Thalmann Financial Services restated a “buy” rating on shares of Stemline Therapeutics in a report on Monday, February 6th. Finally, Cowen and Company restated a “buy” rating on shares of Stemline Therapeutics in a report on Thursday, February 2nd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $24.33.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Shares of Stemline Therapeutics (NASDAQ:STML) traded down 0.59% during mid-day trading on Friday, hitting $8.45. 135,934 shares of the company traded hands. The stock’s market capitalization is $151.69 million. Stemline Therapeutics has a one year low of $4.06 and a one year high of $14.60. The firm has a 50-day moving average of $7.88 and a 200-day moving average of $10.58.

WARNING: “Stemline Therapeutics Inc (STML) Stock Rating Reaffirmed by Wedbush” was originally posted by Web Breaking News and is the sole property of of Web Breaking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at http://www.webbreakingnews.com/2017/03/25/stemline-therapeutics-inc-stml-stock-rating-reaffirmed-by-wedbush.html.

In other news, insider David Gionco sold 3,593 shares of the stock in a transaction dated Thursday, January 19th. The shares were sold at an average price of $11.46, for a total value of $41,175.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Kenneth Hoberman sold 9,110 shares of the stock in a transaction dated Tuesday, January 10th. The shares were sold at an average price of $13.82, for a total transaction of $125,900.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 65,356 shares of company stock valued at $531,879. 16.70% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in STML. Oak Ridge Investments LLC increased its stake in shares of Stemline Therapeutics by 26.3% in the third quarter. Oak Ridge Investments LLC now owns 12,796 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 2,663 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Stemline Therapeutics by 7.9% in the fourth quarter. Renaissance Technologies LLC now owns 65,500 shares of the biopharmaceutical company’s stock valued at $701,000 after buying an additional 4,800 shares in the last quarter. Perceptive Advisors LLC purchased a new stake in shares of Stemline Therapeutics during the fourth quarter valued at approximately $115,000. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 11,300 shares in the last quarter. Finally, State Treasurer State of Michigan purchased a new stake in shares of Stemline Therapeutics during the third quarter valued at approximately $217,000. Institutional investors own 37.76% of the company’s stock.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

5 Day Chart for NASDAQ:STML

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.